

# NICOLA NAPOLI, MD PhD, CURRICULUM VITAE

---

## PERSONAL INFORMATION:

Sex: male

Date of Birth: 30-10-1974

Place of Birth: Agrigento (Italy)

**Citizenship:** italian

### Address and Telephone Numbers:

*Office:* Campus Bio-Medico University of Rome,

Department of Medicine

Unit of Endocrinology & Diabetes

Via Alvaro del Portillo 21,

00128, Roma. ITALY

Phone: +39-06225419151. Fax: +39-0622541456

E-mail: n.napoli@unicampus.it

*Personal:* Via Pomponio Leto, 3

00193, Roma, ITALY

Ph: +39-3475222075

---

## PRESENT POSITION:

- 2017-current: Associate Professor of Endocrinology, Unit of Endocrinology & Diabetes, Campus Bio-Medico University of Rome, Rome, Italy
- 2008-current: Adjunct Assistant Professor of Medicine, Washington University in St Louis, St Louis, MO USA

2018-2024: National Scientific Qualification for Full Professor of Endocrinology

---

## EDUCATION:

- Undergraduate/Graduate Program: Degree in Medicine, magna cum laude (2000)
- Postgraduate
  - 2004: Residency-fellowship in Geriatrics, University of Palermo/ Washington University in St Louis, St Louis MO USA
  - 2007: PhD in Metabolic Diseases, University of Palermo/ Washington University in St Louis, St Louis, MO USA (Mentor, Prof R. Civitelli)

---

## PREVIOUS ACADEMIC POSITIONS / EMPLOYMENT:

- 2012-2017: Assistant Professor of Endocrinology and Metabolism, Unit of Endocrinology & Diabetes, Campus Bio-Medico University of Rome, Rome, Italy
- 2008-2012: Staff Physician, Campus Bio-Medico University of Rome, Rome, Italy

## **UNIVERSITY AND HOSPITAL APPOINTMENTS AND COMMITTEES:**

---

### **University:**

- 2019-current: Head, International Cooperation and Volunteering Committee (CUSV), Campus Bio-Medico University of Rome
- 2013-current: Faculty member, International PhD in Biomedical Sciences and Bio-Ethics, Campus Bio-Medico University of Rome
- 2008-current: Faculty member, Residency-Fellowship program in Endocrinology and Diabetes, Campus Bio-Medico University of Rome
- 2010-2013: Faculty member, PhD program in Osteo-Oncology, Campus Bio-Medico University of Rome
- 2008-2013: Faculty member, International PhD program in Diabetes, Campus Bio-Medico University of Rome

### **Hospital:**

- 2015-present: Clinical coordinator, Unit of Endocrinology & Diabetes, Campus Bio-Medico University of Rome/ ASL Frosinone
- 2008-2015: Staff Physician, Unit of Endocrinology & Diabetes, Campus Bio-Medico University of Rome/ ASL Frosinone
- 2008-2012: volunteer in health campaigns in third world countries
- 2002-2007: visiting physician, Department of Medicine and Department of Emergency, Barnes Jewish Hospital, Washington University Medical Center, St Louis MO USA

## **MEDICAL LICENSURE AND BOARD CERTIFICATION:**

---

- 2000: Medical Licensure
- 2004: Geriatrics, board certification

## **HONORS AND AWARDS:**

---

- 2018: Alcmeone Outstanding Young Investigator Award, Italian Society of Diabetes
- 2016: Ian T Boyle award, European Calcified Tissue Society
- 2014: Harold M. Frost Young Investigator Award, American Society of Bone and Mineral Research (ASBMR)
- 2013: John Haddad Young Investigator Award, ASBMR
- 2011: Presidential Poster Award, ASBMR Annual Conference, San Diego
- 2011: Patrizi Foundation Award, Italian Society of Internal Medicine
- 2010 Junior Career Award, X Congress Italian Society for the Study of Bone and Mineral Skeletal Diseases (SIOMMMS)
- 2009: SIOMMMS Award, Best Medical Paper
- 2009: Best Abstract, IX Congress SIOMMMS
- 2009: August e Marie Krogh Award, Italian Society of Diabetes
- 2008: Young Research Investigator Award, ASBMR Annual Conference, Montreal 09-2008
- 2008: Young Investigator Lecture, VIII Conference, SIOMMMS
- 2007: Young Investigator Travel Award, Endocrine Society Meeting, Toronto
- 2007: Young Investigator Travel Award, ASBMR Annual Conference, Honolulu
- 2006: Young Investigator Travel Award, ASBMR Annual Conference, Philadelphia
- 2005: Young Investigator Award, 3rd Androgen Excess Society Meeting, San Diego

- 2004: Young Investigator Award, Italian Society of Internal Medicine Annual Meeting

#### **EDITORIAL RESPONSIBILITIES:**

---

- 2020-2023: Associate Editor, *Journal of Clinical Endocrinology & Metabolism*
- 2019-2022: Associate Editor, *Endocrine*
- 2016-current: Editorial Board, *Bone*
- 2014-current: Editorial Board, *Journal of Bone and Mineral Research*
- 2013-current: Editorial board, *Osteoporosis International*
- 2013-2014: Associate Editor, *International Journal of Endocrinology*
- 2005-current: Reviewer, *Diabetes Care*, *Bone*, *Journal of Clinical Endocrinology and Metabolism*, *Endocrine*, *Calcified Tissue International*

#### **PROFESSIONAL SOCIETIES AND ORGANIZATIONS:**

---

- American Society for Bone and Mineral Research (ASBMR)
- European Calcified Tissue Society (ECTS)
- Endocrine Society
- Fragility Fracture Network
- European Society of Endocrinology
- Italian Society of Bone and Mineral Diseases (SIOMMMS)
- Italian Society of Diabetes
- Italian Society of Endocrinology
- Italian Society of Geriatrics

#### **MAJOR INVITED PROFESSORSHIPS AND LECTURESHIPS:**

---

- “Bone fragility in diabetes”, Associação Brasileira de Avaliação Óssea e Osteometabolismo annual meeting, October 2020
- “New diabetes treatments and risk of hypoglycaemia”, Diabetes Asia Conference 2020, October 2020
- “Pathophysiology and consequences of Hypoglycaemia”, Egyptian Association of Endocrinology meeting, September 2020
- “Antidiabetic Medications and risk of fracture”, Spanish Society of Diabetes annual meeting, June 2020
- “WNT pathway, diabetes and bone health”, Avioli Lecture, Washington University in St Louis, USA, February 2020
- “Fracture prediction in diabetics”, Aarhus University, Denmark, November 2019
- “Type 1 diabetes and Vitamin D”, Vitamin D international symposium, Gubbio, Italy, September 2019
- “Bone fragility in diabetics”, American University of Beirut, Lebanon, March 2019
- “Application of anabolic treatment in diabetes mellitus”, Innovations in endocrinology-multidisciplinary forum on osteoporosis and other metabolic diseases, Moscow, Russia, October 2018
- “Fracture prediction in the elderly”, Fragility Fracture Network annual meeting, Dublin, July 2018
- “Anabolic treatment of diabetic bone”, Romanian Society of Endocrinology annual meeting, Romania, June 2018

- “Fracture prediction in diabetics”, European Society of Endocrinology annual meeting, Barcelona, Spain, May 2018
- “Bone Sweet Bone”, Alcmeone award lecture, Italian Society of Diabetes annual conference, Rimini, Italy, May 2018
- “New Medical Treatment for Type 2 Diabetes”, International Conference on Diabetes and Obesity, Algiers, Algeria, April 2019
- “Anti-osteoporotic treatment in bone fragility”, The World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO), Krakow, Poland, April 2018
- “The response in bone strength with different treatments for osteoporosis”, Congreso Mexicano de Osteoporosis y Enfermedades Metabolicas Oseas, Guadalajara, Mexico, March 2018
- “Bone fragility: from obesity to Type 2 diabetes”, Avioli Lecture, Washington University in St Louis, November 2017
- “Metabolic surgery for diabetes prevention”, Diabetes Asia 2017 Conference, Kuala Lumpur, Malaysia, October 2017
- “Atypical Femur Fractures, pathogenesis and treatment”, Fragility Fracture Network annual meeting, Malmo, Sweden, August 2017
- “Metformin beyond diabetes: future perspectives of an old molecule (PCOS, obesity)”, 2017 Hot topics in cardiometabolism, Bogotà, Colombia, July 2017
- “Fisiopatologia da fragilidade ossea do paciente com DM2”, Lilly Diabetes Institute Annual Meeting, Brasilia, Brazil, May 2017
- “Diabetes and Bone, why it matters”, 23<sup>rd</sup> Annual Barts Symposium, London, UK, March 2017
- “Bone and diabetes”, Korean Society of Osteoporosis, Seoul, South Korea, November 2016
- “Complicanze a breve e lungo termine della chirurgia bariatrica”, SIOMMMS National Conference, Rome, Italy, October 2016
- “Clinical management of diabetes”, BRADOO annual conference, Joinville, Brazil, October 2016
- “Treating a diabetic patient with bone fragility”, Diabetes and Bone Symposium, 52<sup>nd</sup> EASD Annual Meeting, Munich, Germany, September 2016
- “Myokines (myostatin, irisin and agrin)”, ASBMR annual meeting, Atlanta, USA, September 2016
- “Osteoporosis treatment, past, present and future”, ECTS annual meeting, Rome, Italy, May 2016
- “Cross talk tra beta cellula e osso”, Italian Society of Diabetes annual Conference, Bologna, Italy, May 2016
- “Diabetes and bone fragility”, Diabetes Spanish Society, Bilbao, Spain, April 2016
- “Fat, diabetes and osteoporosis, an update”, University of Sheffield, UK, March 2016
- “Bone sweet bone”, University of Miami, USA, January 2016
- “Treatment of bone disease in diabetics”, Chinese Diabetes Society Meeting, Sozhou, Cina, December 2015
- “Risk of fractures in diabetics”, 7<sup>th</sup> Skeletal Endocrinology Meeting, Brescia, Italy, September 2015
- “Prediabetes, Diabetes and Bone”, 2015 Latin American Conference on Cardiometabolic Diseases Management, Huatulco, Mexico, July 2015
- “Bone Health and Diabetes”, European Society of Calcified Tissue annual meeting, Rotterdam, Holland, April 2015
- “Sweet, Fragile Bone”, Avioli Lecture, Washington University in St Louis, St Louis, USA, March 2015

- “Antidiabetic treatments and bone health”, International Osteoporosis Foundation/ World Osteoporosis Conference, Milan, Italy, March 2015
- “Diabetes: from Pathophysiology to Treatment”: University of Maharashtra, India, February 2015
- “Gastric hormones, diabetes and bone”, Nordic Scientific Bone Meeting, Copenhagen, Denmark, September 2014
- “Bone and Memory after lifestyle intervention”, 44<sup>th</sup> International Musculoskeletal Biology Sun Valley Workshop, Idaho, USA, August 2014
- “Diabetes, Drugs and Osteoporosis”, 6<sup>th</sup> Molecular Pharmacology Workshop, Oxford, UK, June 2014
- “Bone loss and Memory gain during lifestyle intervention”, University of California, San Francisco, USA, June 2014
- “Should we aim to treat diabetes?”, CODHy Latin America Congress, Panama, March 2014
- “Enteric Hormones and Bone Turnover”, Bone Academy, Barcelona, Spain, March 2014
- “Osso e diabete”, Ortomed annual conference, Florence, Italy, December 2013
- “Long term treatment with Bisphosphonates”, University of New Mexico, Albuquerque, USA, September 2013
- “Diabetes and Osteoporosis”, Italian Society of Endocrinology annual meeting, Rome, Italy, June 2013
- “Vitamin D and Diabetes”, Italian Diabetes Association annual meeting, Turin, Italy, May 2012
- “GLP 1 and Bone”, Washington University in St Louis, St Louis, USA, May 2012
- “Insulin-therapy - when, why and which HbA1c target”, Austrian Diabetes Association Meeting, Salzburg, Austria, November 2010
- “New paradigms in type 2 diabetes: after inflammation”, EASD Conference, Stockholm, Sweden, September 2010
- “Professional sport and the diabetic athlete”, The Royal Society of Medicine, London, UK, June 2010
- “Effect of Bisphosphonates on bone quality”, Casa del Sollevo e della Speranza, San Giovanni Rotondo, Italy, March 2010
- “Different phenotypes of diabetes LADA: Combination of type 1 and type 2 diabetes”, 1st Latin America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), Buenos Aires, Argentina, March 2010
- “Technology in underserved patient population: more than optimisation of metabolic control”, ATTD Congress, Basel, Switzerland. February 2010
- “Bone and Diabetes”, Congresso Nazionale, Associazione Medici Endocrinologi, Milan, Italy, November 2009
- “Novel approaches in diabetes care”, University of Tehran, Iran, October 2009
- “New burden in Metabolic Diseases in Third World Countries”, Alexandria, Egypt, October 2009
- “Genetics of estrogen metabolism”, University of Bari, Italy, April 2009
- “Diabetes in emerging countries”, European Association for the Study of Diabetes Annual Meeting (EASD), Rome, Italy, September 2008
- “Memory and bone loss after menopause”, San Raffaele University Hospital, Milan, Italy, April 2007

## **CONSULTING RELATIONSHIPS AND BOARD MEMBERSHIPS:**

---

- 2020-2022: Bone Team Leader, Endocrine Society Annual Meeting Steering Committee (AMSC)
- 2019-2020: American Society for Bone and Mineral Research annual meeting Program Committee Clinical Co-Chair
- 2020-2024: Board Member, President Elect, Italian Society of Diabetes, Lazio Section
- 2009-current: Member, Committee of Scientific Advisors, International Osteoporosis Foundation
- 2019-current: Committee Member, ERC et ATIP-Avenir, National ERC Inserm, France
- 2020: Grant advisor: Swiss National Science Foundation
- 2015-2020: Co-Founder and Board member, Bone Academy, European Society of Calcified Tissue
- 2016-2019: Chairman, Membership, Education and Engagement Committee, ASBMR
- 2018-2019: Member, Endocrine Society AMSC
- 2015-2018: member, Educational Commission, Italian Society of Endocrinology
- 2012 and 2014: Member, Engagement and Educational Committee, ASBMR
- 2010-2014: Member, Advisory Board, Italian Society of Diabetes, Lazio Section
- 2011-2015: Board Member, SIOMMMS
- 2010: Member “ESCEO/ International Osteoporosis Foundation task force of experts for the study of subtrochanteric fractures in patients on long term treatment with bisphosphonates”

## **RESEARCH SUPPORT:**

---

### **Governmental**

- H2020-MSCA-ITN-2019- EU project 860898 – FIDELIO: Training network for research into bone Fragility In Diabetes in Europe – towards a personalLised medlcine approach – 2019-2023 – Co-Principal Investigator
- “Effects of fiber enriched diet on bone and muscle health in elderly obese subjects” (CO-2016-02362346) -€ 300.000- Italian Ministry of Health, 2019-2022 – Principal Investigator
- Clinical and genetic characterization of early complications in juvenile obesity, 2014-2017 – Co-investigator
- “Pancreatic β-cell identity, glucose sensing and the control of insulin secretion”, PRIN 2015, Italian Ministry of Research and Education, 2017-2020, Co-investigator
- “Studio Dell'interazione Tra Metabolismo Glucidico e Osseo per la Caratterizzazione Cardio-Metabolica di una Popolazione di Giovani Obesi”, PRIN 2010-2011 Italian Ministry of Research and Education, 2013-2016 – Sub-investigator
- The interplay between glucose metabolism and the bone metabolism in obese and diabetic patients, Italian Ministry of Research and Education, 2012-2015, Co-Investigator
- “Bisphosphonates and bone material composition”, Italian Ministry of Health - € 240.000 - 2011-2015 – Principal Investigator

### **Non-governmental**

- “Oxidative post-translational modifications of Insulin as biomarkers of type 1 Diabetes” - € 160.000 - Campus Bio-Medico University of Rome, 2019-2020, Principal investigator
- “Bone strength and WNT signalling in obese patients”- € 160.000 - Campus Bio-Medico University of Rome, 2015-2017, Principal Investigator

- “Valutazione della fragilità ossea in un modello sperimentale di Diabete di tipo 1” - €40.000 – SIOMMMS, 2015-2017, Supervisor
- “Evaluation of corneal innervation as a new tool to detect autonomic neuropathy in diabetes” - Fondazione Roma - € 230.000, 2015-2017, Co-Investigator
- “Post-translationally modified insulin as target for therapy in type 1 diabetes”- \$120.000 – Juvenile Diabetes Research Foundation 2015-2017, Co-Investigator
- Effect of Linagliptin on Bone Quality – Boehringer Ingelheim, 2015 – 2017, Principal Investigator
- The effect of calcidiol supplementation on insulin resistance and b-cell function in subjects with impaired glucose metabolism, Bruno Farmaceutici, 2014 – 2016, Principal Investigator
- Role of GLP-1 treatment on Reg Proteins and  $\beta$  cells regeneration in Patients with Type 2 Diabetes, Italian Society of Diabetes, € 25.000 - 2009-2011 - Principal Investigator
- “Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms”, National Institute of Health, USA, PI Dr Reina Villareal, Washington University in St Louis, 2005-2007, Co-Investigator

## **SPONSORED CLINICAL TRIALS**

---

- Co-investigator: PREFER-IT (sponsor ABBOTT)
- Co-investigator: INSAX (sponsor Novo-Nordisk)
- Co-investigator: TROPHIES (sponsor Eli-Lilly)
- Co-investigator: SUSCIPE (sponsor MSD)
- Principal Investigator: Prisma study (sponsor, Roche Diagnostics)
- Co-investigator: MEN/09/zof-ipe/001 (sponsor, Menarini Pharma)
- Co-investigator: LUMI/10/ZOF-HYP/001 (sponsor Lusofarmaco)
- Co-investigator MK0431 (sponsor, MSD)
- EXFOS (principal investigator for Italy, sponsor Ely Lilly)

## **CLINICAL TITLE AND RESPONSIBILITIES:**

---

- Clinical Coordinator, Unit of Endocrinology & Diabetes, Campus Bio-Medico University of Rome/ ASL Frosinone.

## **TEACHING TITLE AND RESPONSIBILITIES:**

---

- Associate Professor, Campus Bio-Medico University of Rome:
  - Endocrinology and Metabolic Diseases (Faculty of Medicine and Surgery)
  - Clinical Nutrition (Faculty of Science and Technology for Humans and the Environment)
- 2005-2008: “Biology of Aging”, University College, Washington University in St Louis
- 2006-2010; 2015: “Bone Biology and Metabolic Bone Diseases”, Program in Physical Therapy, Washington University in St Louis

## **PUBLICATIONS LIST**

---

### **Original Articles**

1. Leanza G, Fontana F, Lee SY, Remedi MS, Schott C, Ferron M, Hamilton-Hall M, Alippe Y, Strollo R, **Napoli N**, Civitelli R. Gain-of-function Lrp5 Mutation Improves Bone Mass and Strength

and Delays Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes. *J Bone Miner Res.* 2021 Apr 8. doi: 10.1002/jbmr.4303. Epub ahead of print.

2. Colleluori G, Aguirre L, **Napoli N**, Qualls C, Villareal DT, Armamento- Villareal R. Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes. *J Clin Endocrinol Metab.* 2021 Mar 18:dgab181. doi: 10.1210/clinem/dgab181. Epub ahead of print.
3. Vigevano F, Gregori G, Colleluori G, Chen R, Autemrongsawat V, **Napoli N**, Qualls C, Villareal DT, Armamento-Villareal R. In Men With Obesity, T2DM Is Associated With Poor Trabecular Microarchitecture and Bone Strength and Low Bone Turnover. *J Clin Endocrinol Metab.* 2021 Apr 23;106(5):1362-1376.
4. Di Mauro A, Tuccinardi D, Watanabe M, Del Toro R, Monte L, Giorgino R, Rampa L, Rossini G, Kyanvash S, Soare A, Rosati M, Piccoli A, **Napoli N**, Fioriti E, Pozzilli P, Khazrai YM, Manfrini S. The Mediterranean diet increases glucagon-like peptide 1 and oxyntomodulin compared with a vegetarian diet in patients with type 2 diabetes: A randomized controlled cross-over trial. *Diabetes Metab Res Rev.* 2020 Sep 14:e3406. doi: 10.1002/dmrr.3406. Epub ahead of print.
5. Piccoli A, Cannata F, Strollo R, Pedone C, Lanza G, Russo F, Greto V, Isgrò C, Quattrocchi CC, Massaroni C, Silvestri S, Vadalà G, Bisogno T, Denaro V, Pozzilli P, Tang SJ, Silva MJ, Conte C, Papalia R, Maccarrone M, **Napoli N**. Sclerostin Regulation, Microarchitecture, And Advanced Glycation End-Products In The Bone Of Elderly Women With Type 2 Diabetes. *J Bone Miner Res.* Volume 35, Issue 12, December 2020, 2415-2422
6. **Napoli N**, Conte C, Eastell R, Ewing SK, Bauer DC, Strotmeyer ES, Black DM, Samelson EJ, Vittinghoff E, Schwartz AV. Bone turnover markers do not predict fracture risk in type 2 diabetes. *J Bone Miner Res.* Volume 35, Issue 12, December 2020, 2363-2371
7. Battisti S, Pedone C, **Napoli N**, Russo E, Agnoletti V, Nigra SG, Dengo C, Mughettoni M, Conte C, Pozzilli P, Giampalma E, Strollo R. Computed Tomography Highlights Increased Visceral Adiposity Associated With Critical Illness in COVID-19. *Diabetes Care.* Volume 43, Issue 10, October 2020, e129-e130
8. Cosman F, Lewiecki EM, Ebeling PR, Hesse E, **Napoli N**, Matsumoto T, Crittenden DB, Rojeski M, Yang W, Libanati C, Ferrari S. T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial. *J Bone Miner Res.* 2020 Jul;35(7):1333-1342.
9. Palermo A, Naciu AM, Tabacco G, Falcone S, Santonati A, Maggi D, D'Onofrio L, Briganti SI, Castellitto D, Casini A, Pedone C, Lelli D, Fabbri A, Bilezikian JP, **Napoli N**, Pozzilli P, Manfrini S, Cesareo R. Clinical, biochemical and radiological profile of normocalcemic primary hyperparathyroidism. *J Clin Endocrinol Metab.* 2020 Jul 1;105(7).
10. Ferrari S, Lewiecki EM, Butler PW, Kendler DL, **Napoli N**, Huang S, Crittenden DB, Pannacciulli N, Siris E, Binkley N. Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. *Bone.* 2020 May;134:115287.

11. Conley RB, Adib G, Adler RA, Åkesson KE, Alexander IM, Amenta KC, Blank RD, Brox WT, Carmody EE, Chapman-Novakofski K, Clarke BL, Cody KM, Cooper C, Crandall CJ, Dirschl DR, Eagen TJ, Elderkin AL, Fujita M, Greenspan SL, Halbout P, Hochberg MC, Javaid M, Jeray KJ, Kearns AE, King T, Koinis TF, Koontz JS, Kužma M, Lindsey C, Lorentzon M, Lyritis GP, Michaud LB, Miciano A, Morin SN, Mujahid N, **Napoli N**, Olenginski TP, Puzas JE, Rizou S, Rosen CJ, Saag K, Thompson E, Tosi LL, Tracer H, Khosla S, Kiel DP. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. *J Orthop Trauma*. 2020 Apr;34(4):e125-e141
12. Ferrari S, Eastell R, **Napoli N**, Schwartz A, Hofbauer LC, Chines A, Wang A, Pannacciulli N, Cummings SR. Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. *Bone*. 2020 May;134:115268.
13. Cannata F, Vadalà G, Ambrosio L, **Napoli N**, Papalia R, Denaro V, Pozzilli P. Osteoarthritis and type 2 diabetes: From pathogenetic factors to therapeutic intervention. *Diabetes Metab Res Rev*. 2020 Mar;36(3):e3254
14. Armamento-Villareal R, Aguirre L, Waters DL, **Napoli N**, Qualls C, Villareal DT. Effect of Aerobic or Resistance Exercise, or Both, on Bone Mineral Density and Bone Metabolism in Obese Older Adults While Dieting: A Randomized Controlled Trial. *J Bone Miner Res*. 2020 Mar;35(3):430-439.
15. Conley RB, Adib G, Adler RA, Akesson KE, Alexander IM, Amenta KC, Blank RD, Brox WT, Carmody EE, Chapman-Novakofski K, Clarke BL, Cody KM, Cooper C, Crandall CJ, Dirschl DR, Eagen TJ, Elderkin AL, Fujita M, Greenspan SL, Halbout P, Hochberg MC, Javaid M, Jeray KJ, Kearns AE, King T, Koinis TF, Koontz JS, Kuzma M, Lindsey C, Lorentzon M, Lyritis GP, Michaud LB, Miciano A, Morin SN, Mujahid N, **Napoli N**, Olenginski TP, Puzas JE, Rizou S, Rosen CJ, Saag K, Thompson E, Tosi LL, Tracer H, Khosla S, Kiel D. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. *J Bone Miner Res*. 2020 Jan;35(1):36-52
16. Cannata F, Vadalà G, Ambrosio L, Fallucca S, **Napoli N**, Papalia R, Pozzilli P, Denaro V. Intervertebral disc degeneration: a focus on obesity and type 2 diabetes. *Diabetes Metab Res Rev*. 2019 Oct 23:e3224.
17. Marcucci G, Beltrami G, Tamburini A, Body JJ, Confavreux CB, Hadji P, Holzer G, Kendler D, **Napoli N**, Pierroz DD, Rizzoli R, Brandi ML. Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors. *Ann Oncol*. 2019 Jun 1;30(6):908-920
18. Leanza G, Maddaloni E, Pitocco D, Conte C, Palermo A, Maurizi AR, Lauria Pantano A, Suraci C, Altomare M, Strollo R, Pozzilli P, Schwartz AV, **Napoli N**. Risk Factors for Fragility Fractures in Type 1 Diabetes. *Bone*, 2019 Aug;125:194-199
19. Strollo R, Vinci C, **Napoli N**, Fioriti E, Maddaloni E, Åkerman L, Casas R, Pozzilli P, Ludvigsson J, Nissim A. Antibodies to oxidized insulin improve prediction of type 1 diabetes in children with positive standard islet autoantibodies. *Diabetes Metab Res Rev*. 2019 May;35(4):e3132

20. Pieralice S, Vari R, Minutolo A, Maurizi AR, Fioriti E, **Napoli N**, Pozzilli P, Manfrini S, Maddaloni E. Biomarkers of response to alpha-lipoic acid ± palmitoletanolamide treatment in patients with diabetes and symptoms of peripheral neuropathy. *Endocrine.*, 2019 Nov;66(2):178-184
21. **Napoli N**, Conte C, Pedone C, Strotmeyer ES, Barbour KE, Black DM, Samelson EJ, Schwartz AV. Effect of Insulin Resistance on BMD and Fracture Risk in Older Adults. *J Clin Endocrinol Metab.*, 2019 Aug 1;104(8):3303-3310
22. Palermo A, Sanesi L, Colaianni G, Tabacco G, Naciu AM, Cesareo R, Pedone C, Lelli D, Brunetti G, Mori G, Colucci S, Manfrini S, **Napoli N**, Grano M. A novel interplay between irisin and PTH: from basic studies to clinical evidence in hyperparathyroidism. *J Clin Endocrinol Metab.*, 2019 Aug 1;104(8):3088-3096
23. K Giri T, Newton D, Chaudhary O, Deych E, **Napoli N**, Villareal R, Diemer K, E Milligan P, F Gage B. Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis. *Int J Vitam Nutr Res.*, 2019; 28:1-7.
24. Tabacco G, Naciu AM, Maggi D, Santonati A, Pedone C, Cesareo R, Bosco D, Gaspa G, **Napoli N**, Pozzilli P, Manfrini S, Palermo A. Cardiovascular Autonomic Neuropathy as a New Complication of Postsurgical Chronic Hypoparathyroidism. *J Bone Miner Res.*, 2019 Mar; 34:475-481.
25. Silverman S, Langdahl BL, Fujiwara S, Saag K, **Napoli N**, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies. *Calcif Tissue Int.*, 2019; 104:193-200.
26. Bertoccini L, Bailetti D; SUMMER Study in Diabetes Group, Buzzetti R, Cavallo MG, Copetti M, Cossu E, D'Angelo P, De Cosmo S, Di Mauro L, Leonetti F, Morano S, Morviducci L, **Napoli N**, Prudente S, Pugliese G, Trischitta V, Baroni MG. Variability in genes regulating vitamin D metabolism is associated with vitamin D levels in type 2 diabetes. *Oncotarget.*, 2018; 9:34911-34918.
27. Langdahl BL, Silverman S, Fujiwara S, Saag K, **Napoli N**, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. *Bone.*, 2018 Nov; 116:58-66.
28. Colleuori G, Chen R, **Napoli N**, Aguirre LE, Qualls C, Villareal DT, Armamento-Villareal R. Fat Mass Follows a U-Shaped Distribution Based on Estradiol Levels in Postmenopausal Women. *Front Endocrinol (Lausanne)*, 2018 Jul; 9:315.
29. **Napoli N**, Langdahl BL, Ljunggren Ö, Lespessailles E, Kapetanos G, Kocjan T, Nikolic T, Eiken P, Petto H, Moll T, Lindh E, Marin F. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from European Extended Forsteo® Observational Study (ExFOS). *Calcif Tissue Int.*, 2018 Oct; 103:359-371.

30. **Napoli N**, Pannacciulli N, Vittinghoff E, Crittenden D, Yun J, Wang A, Wagman R, Schwartz AV. Effect of Denosumab on Fasting Glucose in Women With Diabetes or Prediabetes From the FREEDOM Trial. *Diabetes Metab Res Rev.*, 2018 May; 34:e2991.
31. **Napoli N**, Strollo R., Defeudis G., Leto G., Zampetti S., D'Onofrio L., Campagna G., Palermo A., Greto V., Manfrini S., Hawa M., Leslie D., Buzzetti R. Serum sclerostin and bone turnover in latent autoimmune diabetes in adults. *J Clin Endocrinol Metab.*, 2018 May 1; 103:1921-1928.
32. Colleuori G, **Napoli N**, Phadnis U, Armamento-Villareal R, Villareal DT. Effect of Weight Loss, Exercise, or Both on Undercarboxylated Osteocalcin and Insulin Secretion in Frail, Obese Older Adults. *Oxid Med Cell Longev.*, 2017; 2017:4807046.
33. **Napoli N**, Schwartz AV, Schafer AL, Vittinghoff E, Cawthon P, Parimi N, Orwoll E, Strotmeyer ES, Hoffman AR, Barrett-Connor E, Black DM; Osteoporotic Fractures in Men (MrOS) Study Research Group. Vertebral Fracture Risk in Diabetic Elderly Men: The MrOS Study. *J Bone Miner Res.*, 2018 Jan; 33:63-69.
34. Black DM, Cauley JA, Wagman R, Ensrud K, Fink HA, Hillier TA, Lui LY, Cummings SR, Schousboe JT, **Napoli N**. The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures. *J Bone Miner Res.*, 2018 Mar; 33:389-395.
35. Strollo R, Vinci C, **Napoli N**, Pozzilli P, Ludvigsson J, Nissim A. Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children. *Diabetologia.*, 2017 Aug; 60:1467-1474.
36. Maddaloni E, D'Eon S, Hastings S, Tinsley LJ, **Napoli N**, Khamaisi M, Bouxsein ML, Fouda SM, Keenan HA. Bone health in subjects with type 1 diabetes for more than 50 years. *Acta Diabetol.*, 2017 May; 54:479-488.
37. Strollo R, Soare A, Manon Khazrai Y, Di Mauro A, Palermo A, Del Toro R, Fallucca S, Giovanna Belluomo M, Dugo L, Pianesi M, Pozzilli P, **Napoli N**. Increased sclerostin and bone turnover after diet-induced weight loss in type 2 diabetes: a post hoc analysis of the MADIBA trial. *Endocrine.*, 2017 Jun; 56:667-674.
38. Ensrud KE, Harrison SL, Cauley JA, Langsetmo L, Schousboe JT, Kado DM, Gourlay ML, Lyons JG, Fredman L, **Napoli N**, Crandall CJ, Lewis CE, Orwoll ES, Stefanick ML, Cawthon PM; Osteoporotic Fractures in Men (MrOS) Research Group. Impact of Competing Risk of Mortality on Association of Weight Loss with Risk of Central Body Fractures in Older Men: A Prospective Cohort Study. *J Bone Miner Res.*, 2017 Mar; 32:624-632.
39. Palermo A, Mangiameli G, Tabacco G, Longo F, Pedone C, Briganti SI, Maggi D, Vescini F, Naciu A, Lauria Pantano A, **Napoli N**, Angeletti S, Pozzilli P, Crucitti P, Manfrini S. PTH(1-34) for the primary prevention of post-thyroidectomy hypocalcemia: the THYPOS trial. *J Clin Endocrinol Metab.*, 2016 Nov; 101:4039-4045.

40. **Napoli N**, Schafer AL, Lui LY, Cauley JA, Strotmeyer ES, Le Blanc ES, Hoffman AR, Lee CG, Black DM, Schwartz AV. Serum 25-hydroxyvitamin D level and incident type 2 diabetes in older men, the Osteoporotic Fractures in Men (MrOS) study. *Bone*., 2016 Sep; 90:181-4.
41. Langdahl BL, Ljunggren Ö, Benhamou CL, Marin F, Kapetanos G, Kocjan T, Lespessailles E, **Napoli N**, Nikolic T, Petto H, Moll T, Lindh E. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS). *Calcif Tissue Int*., 2016 Sep; 99:259-71.
42. Armamento-Villareal R, Wingkun N, Aguirre LE, Kulkarny V, **Napoli N**, Colleluori G, Qualls C, Villareal DT. The FTO gene is associated with a paradoxically favorable cardiometabolic risk profile in frail, obese older adults. *Pharmacogenet Genomics*., 2016 Apr; 26:154-160.
43. Musumeci M, Palermo A, D'Onofrio L, Vadalà G, Greto V, Di Stasio E, Maddaloni E, Di Rosa M, Tibullo D, Silvia A, **Napoli N**, Denaro V, Manfrini S. Serum chitotriosidase in postmenopausal women with severe osteoporosis. *Osteoporos Int*., 2016 Feb; 27:717.
44. **Napoli N**, Rastelli A, Ma C, Colleluori G, Vattikuti S, Armamento-Villareal R. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer. *Pharmacogenet Genomics*., 2015 Aug; 25:377-81.
45. Palermo A, Strollo R, Maddaloni E, Tuccinardi D, D'Onofrio L, Briganti SI, Defeudis G, De Pascalis M, Lazzaro MC, Colleluori G, Manfrini S, Pozzilli P, **Napoli N**. Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition or daily physical activity. *Clin Endocrinol (Oxf)*., 2015 Apr; 82:615-9.
46. Vivian Ma YH, Schwartz AV, Sigurdsson S, Hue TF, Lang TF, Harris TB, Rosen CJ, Vittinghoff E, Eriksdottir G, Hauksdottir AM, Siggeirsottir K, Sigurdsson G, Oskarsdottir D, **Napoli N**, Palermo L, Gudnason V, Li X. Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. *J Clin Endocrinol Metab*., 2014 Dec; 99:E2584-90.
47. Rini GB, Sprini D, Migliaccio S, Basili S, Strollo R, Dieli F, **Napoli N**. Vγ9 Vδ2 T lymphocytes activation as a novel approach to test efficacy of different bisphosphonates. *Endocrine*., 2015 Feb; 48:346-8.
48. **Napoli N**, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Hoffman AR, Dam TT, Barrett-Connor E, Palermo L, Orwoll ES, Cummings SR, Black DM, Schwartz AV. Fracture risk in diabetic elderly men: the MrOS study. *Diabetologia*., 2014 Oct; 57:2057-65.
49. Aguirre L, **Napoli N**, Waters D, Qualls C, Villareal DT, Armamento-Villareal R. Increasing Adiposity Is Associated With Higher Adipokine Levels and Lower Bone Mineral Density in Obese Older Adults. *J Clin Endocrinol Metab*., 2014 Sep; 99:3290-7.
50. Maddaloni E, D'Onofrio L, Lauria A, Maurizi AR, Strollo R, Palermo A, **Napoli N**, Angeletti S, Pozzilli P, Manfrini S. Osteocalcin levels are inversely associated with Hba1c and BMI in adult subjects with long-standing type 1 diabetes. *J Endocrinol Invest*., 2014 Jul; 37:661-6.
51. **Napoli N**, Shah K, Waters DL, Sinacore DR, Qualls C, Villareal DT. Effect of weight loss,

exercise, or both on cognition and quality of life in obese older adults. *Am J Clin Nutr.*, 2014 Apr; 100:189-198.

52. Ljunggren O, Benhamou CL, Dekker J, Kapetanos G, Kocjan T, Langdahl BL, **Napoli N**, Petto H, Nikolić T, Lindh E. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS). *Curr Med Res Opin.*, 2014 Aug; 30:1607-16.
53. Schafer AL, **Napoli N**, Lui L, Schwartz AV, Black DM; Study of Osteoporotic Fractures. Serum 25-hydroxyvitamin D concentration does not independently predict incident diabetes in older women. *Diabet Med.*, 2014 May; 31:564-9.
54. **Napoli N**, Rastelli A, Ma C, Yarramaneni J, Vattikutti S, Moskowitz G, Giri T, Mueller C, Kulkarny V, Qualls C, Ellis M, Armamento-Villareal R. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer. *Bone.*, 2013 Aug; 55:309-14.
55. Bouchonville M, Armamento-Villareal R, Shah K, **Napoli N**, Sinacore DR, Qualls C, Villareal DT. Weight loss, exercise or both and cardiometabolic risk factors in obese older adults: results of a randomized controlled trial. *Int J Obes (Lond).*, 2014 Mar; 38:423-31.
56. **Napoli N**, Strollo, R., Sprini, D., Maddaloni, E., Rini, G.B., Carmina, E, Serum 25-OH vitamin D in relation to bone mineral density and bone turnover. *Int J Endocrinology.*, 2014; 2014:48.
57. Pedone C, **Napoli N**, Pozzilli P, Lauretani F, Bandinelli S, Ferrucci L, Rossi FF, Antonelli Incalzi R. Bone health as a function of adipokines and vitamin D pattern in elderly patients. *Rejuvenation Res.*, 2013 Dec; 16:467-74.
58. Armamento-Villareal R, Aguirre L, **Napoli N**, Shah K, Hilton T, Sinacore DR, Qualls C, Villareal DT. Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adults. *Osteoporos Int.*, 2014 Feb; 25:551-8.
59. Pedone C, Scarlata S, **Napoli N**, Lauretani F, Bandinelli S, Ferrucci L, Incalzi RA. Relationship Between Bone Cross-Sectional Area and Indices of Peripheral Artery Disease. *Calcif Tissue Int.*, 2013 Dec; 93:508-16.
60. **Napoli N**, Strollo R, Pitocco D, Bizzarri C, Maddaloni E, Maggi D, Manfrini S, Schwartz A, Pozzilli P; I.M.D.I.A.B. Group. Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes. *PloS One.*, 2013; 8:e56488.
61. **Napoli N**, Schwartz AV, Palermo L, Jin JJ, Wustrack R, Cauley JA, Ensrud KE, Kelly M, Black DM. Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures. *J Clin Endocrinol Metab.*, 2013 Feb; 98:659-67.
62. Strollo R, Rizzo P, Spoletini M, Landy R, Hughes C, Ponchel F, **Napoli N**, Palermo A, Buzzetti R, Pozzilli P, Nissim A. HLA dependent auto-antibodies against post-translationally modified collagen type II in Type 1 Diabetes Mellitus. *Diabetologia.*, 2013 Mar; 56:563-72.

63. **Napoli N**, Zardi E, Strollo R, Dicuonzo G, Scarpa F, Pedone C, Tegue Simo HH, Mottini G, Pozzilli P. Increased carotid thickness in subjects with recently-diagnosed diabetes from rural Cameroon. *PLOS One.*, 2012; 7:e41316.
64. **Napoli N**, Jin J, Peters K, Wustrack R, Burch S, Chau A, Cauley J, Ensrud K, Kelly M, Black DM. Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures. *J Clin Endocrinol Metab.*, 2012 Jul; 97:2414-22.
65. Armamento-Villareal R, Sadler C, **Napoli N**, Shah K, Chode S, Sinacore DR, Qualls C, Villareal DT. Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. *J Bone Miner Res.*, 2012 May; 27:1215-21.
66. **Napoli N**, Vattikuti S, Yarramaneni J, Giri TK, Nekkalapu S, Qualls C, Armamento-Villareal RC. Increased 2-hydroxylation of estrogen is associated with lower body fat and increased lean body mass in postmenopausal women. *Maturitas.*, 2012 May; 72:66-71.
67. Shah K, Armamento-Villareal R, Parimi N, Chode S, Sinacore DR, Hilton TN, **Napoli N**, Qualls C, Villareal DT. Exercise training in obese older adults prevents increase in bone turnover and attenuates decrease in hip bone mineral density induced by weight loss despite decline in bone-active hormones. *J Bone Miner Res.*, 2011 Dec; 26:2851-9.
68. Rastelli AL, Taylor ME, Gao F, Armamento-Villareal R, Jamalabadi-Majidi S, **Napoli N**, Ellis MJ. Vitamin D and aromatase inhibitor-induced Musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. *Breast Cancer Res Treat.*, 2011 Aug; 129:107-16
69. **Napoli N**, Pedone C, Pozzilli P, Lauretani F, Bandinelli S, Ferrucci L, Incalzi RA. Effect of ghrelin on bone mass density: The InChianti study. *Bone.*, 2011, Aug; 49:257-63.
70. Villareal DT, Chode S, Parimi N, Sinacore DR, Hilton T, Armamento-Villareal R, **Napoli N**, Qualls C, Shah K. Weight loss, exercise, or both and physical function in obese older adults. *N Engl J Med.*, 2011 Mar; 364:1218-29.
71. Palermo A, **Napoli N**, Manfrini S, Lauria A, Strollo R, Pozzilli P. Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study. *Diabetes Obes Metab.*, 2011 Jan; 13:42-6
72. Iacobellis, G., Iorio, M., **Napoli N**, Cotesta, D., Zinnamosca, L., Marinelli, C., Petramala, L., Minisola, S., D'Erasmo, E., Letizia, C., Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. *J Endocrinol Invest.*, 2011 Jan; 34:e12-5.
73. Di Stasio, E., Maggi, D., Berardesca, E., Marulli, G.C., Bizzarri, C., Lauria, A., Portuesi, R., Cavallo, M.G., Costantino, F., Buzzetti, R., Astorri, E., Pitocco, D., Songini, M., Pozzilli, P., Altomare, M., Astorri, E., Barchetta, I., Benevento, D., Beretta Anguissola, G., Bizzarri, C., Buzzetti, R., Capizzi, M., Cappa, **Napoli, N.**, et al., Blue eyes as a risk factor for type 1 diabetes. *Diabetes Metab Res Rev.*, 2011 Sep; 27:609-13.
74. **Napoli N**, Vattikuti S, Ma C, Rastelli A, Rayani A, Donepudi R, Asafdar M, Yarramaneni J,

Ellis M, Armamento-Villareal R. High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer. *Breast J.*, 2010 Nov-Dec; 16:609-16.

75. Bizzarri C, Pitocco D, **Napoli N**, Di Stasio E, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P; IMDIAB Group. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. *Diabetes Care.*, 2010 Sep; 33:1962-3.
76. **Napoli N**, Pedone C, Pozzilli P, Lauretani F, Ferrucci L, Incalzi RA. Adiponectin and bone mass density: The InCHIANTI study. *Bone.*, 2010 Dec; 47:1001-5.
77. **Napoli N**, Costanza F, Di Stasio E, Strollo R, Manfrini S, Cipponeri E, Picardi A, Carrano F, Dell'anna V, Macino W, Pozzilli P. Blood glucose monitoring in the normal population: the PREDICA study. *Acta Diabetol.*, 2011 Mar; 48:29-34.
78. Difede G, Scalzo G, Buccieri S, Moretti G, Campisi G, **Napoli N**, Battista Rini G, Guglielmi G. Underreported vertebral fractures in an Italian population: comparison of plain radiographs vs quantitative measurements. *Radiol Med.*, 2010 Oct; 115:1101-10.
79. Occhicone F, Quattrocchi CC, **Napoli N**, Dell'Aia P, D'Agostino F, Pozzilli P, Beomonte Zobel B. Incidence of new fractures in women with osteoporosis-induced vertebral fractures detected on routine lateral chest radiographs. *Radiol Med.*, 2010 Aug; 115:815-25.
80. Early DS, Gao F, Ver CY, Nagler A, Cole E, Gorbe E, **Napoli N**, Armamento-Villareal R. The association between a functional CYP1A1 polymorphism and colorectal neoplasia risk in post menopausal women. *Dig Dis Sci.*, 2010 Oct; 55:2965-70.
81. Pedone C, **Napoli N**, Pozzilli P, Lauretani F, Bandinelli S, Ferrucci L, Antonelli-Incalzi R. Quality of diet and potential renal acid load as risk factors for reduced bone density in elderly women. *Bone.*, 2010 Apr; 46:1063-7.
82. **Napoli N**, Mottini G, Arigliani M, Creta A, Giua R, Incammisa A, Carotti S, Sihom F, Yimagou I, Alombah R, Mbanya JC, Pozzilli P. Unexpectedly high rates of obesity and dysglycemia among villagers in Cameroon. *Diabetes Metab Res Ver.*, 2010 Jan; 26:10-2.
83. Armamento-Villareal R, **Napoli N**, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. *Calcif Tissue Int.*, 2009 Jul; 85:37-44.
84. **Napoli N**, Varadharajan A, Rini GB, Del Facco R, Yarramaneni J, Mumm S, Villareal DT, Armamento-Villareal R. Effects of polymorphisms of the sex hormone-binding globulin (SHBG) gene on free estradiol and bone mineral density. *Bone.*, 2009 Dec; 45:1169-74.
85. **Napoli N**, Rini GB, Serber D, Giri T, Yarramaneni J, Buccieri S, Camarda L, Di Fede G, Camarda MR, Jain S, Mumm S, Armamento-Villareal R. The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density. *Bone.*, 2009 Mar; 44:442-8.
86. **Napoli N**, Thompson J, Civitelli R, Armamento-Villareal RC. Effects of dietary calcium

compared with calcium supplements on estrogen metabolism and bone mineral density. *Am J Clin Nutr.*, 2007 May; 85:1428-33.

87. **Napoli N**, Faccio R, Shrestha V, Bucchieri S, Rini GB, Armamento-Villareal R. Estrogen metabolism modulates bone density in men. *Calcif Tissue Int.*, 2007 Apr; 80:227-32. (
88. Falchetti A, Sferrazza C, Cepollaro C, Gozzini A, Del Monte F, Masi L, **Napoli N**, Di Fede G, Cannone V, Cusumano G, Pandolfo MC, Rini GB, Tanini A, Brandi ML. FokI polymorphism of the vitamin D receptor gene correlates with parameters of bone mass and turnover in a female population of the Italian island of Lampedusa. *Calcif Tissue Int.*, 2007 Jan; 80:15-20.
89. **Napoli N**, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. *Bone.*, 2006 Jun; 38:888-92.
90. Carmina E, **Napoli N**, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. *Eur J Endocrinol.*, 2006 Jan; 154:141-5.
91. **Napoli N**, Villareal DT, Mumm S, Halstead L, Sheikh S, Cagaanan M, Rini GB, Armamento-Villareal R. Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. *J Bone Miner Res.*, 2005 Feb; 20:232-9.
92. **Napoli N**, Donepudi S, Sheikh S, Rini GB, Armamento-Villareal R. Increased 2-hydroxylation of estrogen in women with a family history of osteoporosis. *J Clin Endocrinol Metab.*, 2005 Apr; 90:2035-41.
93. Di Lorenzo G, Pacor ML, Mansueto P, Martinelli N, Esposito-Pellitteri M, Lo Bianco C, Ditta V, Leto-Barone MS, **Napoli N**, Di Fede G, Rini G, Corrocher R. Food-additive-induced urticaria: a survey of 838 patients with recurrent chronic idiopathic urticaria. *Arch Allergy Immunol.*, 2005 Nov; 138:235-4.
94. Armamento-Villareal R, Sheikh S, Nawaz A, **Napoli N**, Mueller C, Halstead LR, Brodt MD, Silva MJ, Galbiati E, Caruso PL, Civelli M, Civitelli R. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized. *J Bone Miner Res.*, 2005 Dec; 20:2178-88.
95. Di Lorenzo G, Pacor ML, Mansueto P, Esposito Pellitteri M, Lo Bianco C, Ditta V, Leto-Barone MS, **Napoli N**, Di Fede G, Rini GB. Determinants of bronchial hyperresponsiveness in subjects with rhinitis. *Int J Immunopathol Pharmacol.*, 2005 Oct-Dec; 18:715-22.
96. Armamento-Villareal RC, **Napoli N**, Klug T, Civitelli R. The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women. *Bone.*, 2004 Sep; 35:682-8.
97. Carmina E, Di Fede G, **Napoli N**, Renda G, Vitale G, Lo Pinto C, Bruno D, Malizia R, Rini GB. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. *Calcif Tissue Int.*, 2004 Jan; 74:68-71.

## Reviews, perspectives and editorials

98. Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, Madhavan MV, Nair N, Babalyan V, Hutchings N, Napoli N, Accili D, Binkley N, Landry DW, Giustina A. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. *Eur J Endocrinol.* 2020 Nov;183(5):R133-R147. doi: 10.1530/EJE-20-0665.
99. Lems WF, Paccou J, Zhang J, Fuggle NR, Chandran M, Harvey NC, Cooper C, Javaid K, Ferrari S, Akesson KE; International Osteoporosis Foundation Fracture Working Group. Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. *Osteoporos Int.* 2021 Mar;32(3):399-411.
100. Briganti SI, Naciu AM, Tabacco G, Cesareo R, **Napoli N**, Trimboli P, Castellana M, Manfrini S, Palermo A. Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature. *Int J Endocrinol.* 2021 Jan 15;2021:8902367.
101. Cannata F, Vadalà G, Ambrosio L, Papalia R, **Napoli N**. Nutritional Therapy for Athletes with Diabetes. *J Funct Morphol Kinesiol.* 2020 Nov 13;5(4):83.
102. Cannata F, Vadalà G, Russo F, Papalia R, **Napoli N**, Pozzilli P. Beneficia Effects of Physical Activity in Diabetic Patients. *J Funct Morphol Kinesiol.* 2020 Sep 4;5(3):70.
103. Giustina A, Bouillon R, Binkley N, Sempos C, Adler RA, Bollerslev J, Dawson- Hughes B, Ebeling PR, Feldman D, Heijboer A, Jones G, Kovacs CS, Lazaretti- Castro M, Lips P, Marcocci C, Minisola S, **Napoli N**, Rizzoli R, Scragg R, White JH, Formenti AM, Bilezikian JP. Controversies in Vitamin D: A Statement From the Third International Conference. *JBMR Plus.* 2020 Nov 10;4(12):e10417.
104. Falchetti A, Mohseni M, Tramontana F, **Napoli N**. Secondary prevention of fragility fractures: where do we stand during the COVID-19 pandemic? *J Endocrinol Invest.* 2021 Apr 17:1-4. doi: 10.1007/s40618-021-01552-1. Epub ahead of print. PMID: 33864609;
105. **Napoli N**, Incalzi RA, De Gennaro G, Marcocci C, Marfella R, Papalia R, Purrello F, Ruggiero C, Tarantino U, Tramontana F, Conte C. Bone fragility in patients with diabetes mellitus: A consensus statement from the working group of the Italian Diabetes Society (SID), Italian Society of Endocrinology (SIE), Italian Society of Gerontology and Geriatrics (SIGG), Italian Society of Orthopaedics and Traumatology (SIOT). *Nutr Metab Cardiovasc Dis.* 2021 Feb 4:S0939-4753(21)00039-9. doi: 10.1016/j.numecd.2021.01.019. Epub ahead of print.
106. Anastasilakis AD, Tsourdi E, Tabacco G, Naciu AM, **Napoli N**, Vescini F, Palermo A. The Impact of Antiosteoporotic Drugs on Glucose Metabolism and Fracture Risk in Diabetes: Good or Bad News? *J Clin Med.* 2021 Mar 2;10(5):996.
107. **Napoli N**, Elderkin AL, Kiel DP, Khosla S. Managing fragility fractures during the COVID-19 pandemic. *Nat Rev Endocrinol.* 2020 Sep;16(9):467-468
108. Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, Madhavan MV, Nair N, Babalyan V, Hutchings NJ, **Napoli N**, Accili D, Binkley N, Landry DW,

Giustina A. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. *Eur J Endocrinol.* 2020 Aug 1:EJE-20-0665.R1.

109. Ripamonti CI, **Napoli N**. Are We Ready to Use Teriparatide to Treat Medication-Related Osteonecrosis of the Jaw in Clinical Practice? *J Clin Oncol.* 2020 Sep 10;38(26):2949-2951.
110. Chakhtoura M, **Napoli N**, El Hajj Fuleihan G. Myths and facts on vitamin D amidst the COVID-19 pandemic. *Metabolism.* 2020 Aug;109:154276
111. Tramontana F, **Napoli N**, El-Hajj Fuleihan G, Strollo R. The D-side of COVID-19: musculoskeletal benefits of vitamin D and beyond. *Endocrine.* 2020 Aug;69(2):237-240
112. Black DM, Abrahamsen B, Bouxsein M, **Napoli N**. Atypical Femur Fractures – Review of epidemiology, relationship to BP, prevention and clinical management. *Endocr Rev.* 2019 Apr; 40:333-368.
113. Picke AK, Campbell G, **Napoli N**, Hofbauer LC, Rauner M. Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. *Endocr Connect.* 2019 Mar; 8:R55-R70.
114. Cavallari I, Delli Veneri A, Maddaloni E, Melfi R, Patti G, **Napoli N**, Pozzilli P, Di Sciascio G. Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. *Curr Diab Rep.*, 2018 Oct; 18:138.
115. Pieralice S, Vigevano F, Del Toro R, **Napoli N**, Maddaloni E. Lifestyle Management of Diabetes: Implications for the Bone-Vascular Axis. *Curr Diab Rep.*, 2018 Aug; 18:84.
116. Ebeling P, Adler R, Jones G, Liberman UA, Mazziotti G, Minisola S, Munns C, **Napoli N**, Pittas A, Giustina A, Bilezikian JP, Rizzoli R. Management of Endocrine Diseases: Therapeutics of Vitamin D. *Eur J Endocrinol.*, 2018 Oct; 179:R239-R259.
117. Ferrari SL, Abrahamsen B, **Napoli N**, Akesson K, Chandran M, Eastell R, El-Hajj Fuleihan G, Josse R, Kendler DL, Kraenzlin M, Suzuki A, Pierroz DD, Schwartz AV, Leslie WD; Bone and Diabetes Working Group of IOF. Diagnosis and management of bone fragility in diabetes: an emerging challenge. *Osteoporos Int.*, 2018 Dec; 29:2585-2596.
118. Maddaloni E, Cavallari I, **Napoli N**, Conte C. Vitamin D and Diabetes Mellitus. *Front Horm Res.*, 2018; 50:161-176.
119. Conte C, Epstein S, **Napoli N**. Insulin resistance and bone: a biological partnership. *Acta Diabetol.*, 2018 Apr; 55:305-314.
120. Iolascon G, Gimigliano R, Bianco M, De Sire A, Moretti A, Giusti A, Malavolta N, Migliaccio S, Migliore A, **Napoli N**, Piscitelli P, Resmini G, Tarantino U, Gimigliano F. Are Dietary Supplements and Nutraceuticals Effective for Musculoskeletal Health and Cognitive Function? A Scoping Review. *J Nutr Health Aging.*, 2017; 21:527-538.
121. Palermo A, Tuccinardi D, D'Onofrio L, Watanabe M, Maggi D, Maurizi AR, Greto V, Buzzetti

- R, **Napoli N**, Pozzilli P, Manfrini S. Vitamin K and osteoporosis: Myth or reality? *Metabolism.*, 2017 May; 70:57-71.
122. Palermo A, D'Onofrio L, Buzzetti R, Manfrini S, **Napoli N**. Pathophysiology of Bone Fragility in Patients with Diabetes. *Calcif Tissue Int.*, 2017 Feb; 100:122-132.
123. **Napoli N**, Chandran M., Pierroz D., Abrahamsen B., Schwartz AV, Ferrari S. Mechanisms of diabetes mellitus-induced bone fragility. *Nature Reviews Endocrinology.*, 2017 Apr; 13:208-219.
124. Masi L, Agnusdei D, Bilezikian J, Chappard D, Chapurlat R, Cianferotti L, Devogelaer JP, El Maghraoui A, Ferrari S, Javaid MK, Kaufman JM, Liberman UA, Lyritis G, Miller P, **Napoli N**, Roldan E, Papapoulos S, Watts NB, Brandi ML. Taxonomy of rare genetic metabolic bone disorders. *Osteoporos Int.*, 2015 Nov; 26:2717-8.
125. Epstein, S., Defeudis, G., Manfrini, S., **Napoli N**, Pozzilli, P. Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition. *Osteoporos Int.*, 2016 27:1931-51.
126. Palermo, A., Tuccinardi, D., Defeudis, G., Watanabe, M., D'Onofrio, L., Lauria, A., **Napoli N**, Pozzilli, P., Manfrini, S., BMI and BMD: The potential interplay between obesity and bone fragility. *Int J Environ Res Public Health.*, 2016 May; 13.
127. Palermo A., D'Onofrio L, P. Pozzilli, **Napoli N**, Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? *Osteoporos Int.*, 2015 Aug; 26:2073-89.
128. Armamento-Villareal R, **Napoli N**, Waters D, Villareal D. Fat, muscle, and bone interactions in obesity and the metabolic syndrome. *Int J Endocrinol.*, 2014; 2014:247076.
129. **Napoli N**, Strollo R, Paladini A, Briganti SI, Pozzilli P, Epstein S. The alliance of mesenchymal stem cells, bone, and diabetes. *Int J Endocrinology.*, 2014; 2014:690783.
130. Sprini D, Rini GB, Di Stefano L, Cianferotti L, **Napoli N**, Correlation between osteoporosis and cardiovascular disease. *Clin Cases Miner Bone Metab*, 2014 May; 11:117-9.
131. **Napoli N**. Questions on therapy with DPP-4 inhibitors and bone homeostasis. *Diabetes Metab Res Rev*, 2014 Mar; 30:201-3.
132. Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, Glüer CC, Kendler D, **Napoli N**, Papaioannou A, Pierroz DD, Rahme M, Van Poznak CH, de Villiers TJ, El Hajj Fuleihan G; International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease. Cancer-associated bone disease. *Osteoporos Int.*, 2013 Dec; 24:2929-5313.
133. Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, **Napoli N**, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE; Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-

- induced osteoporosis. *Osteoporos Int.*, 2012 Sep; 23:2257-76.
134. Brunetti G, Oranger A, Mori G, Sardone F, Pignataro P, Coricciati M, **Napoli N**, Rizzi R, Liso V, Grassi FR, Grano M, Colucci S. TRAIL effect on osteoclast formation in physiological and pathological conditions. *Front Biosci (Elite Ed.)*, 2011 Jun; 3:1154-61.
135. Rizzoli R, Akesson K, Bouxsein M, Kanis JA, **Napoli N**, Papapoulos S, Reginster JY, Cooper C. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. *Osteoporos Int.*, 2011 Feb; 22:373-90.
136. Santini D, Fratto ME, Vincenzi B, **Napoli N**, Galluzzo S, Tantardini M, Abbruzzese A, Caraglia M, Tonini G. Denosumab: the era of targeted therapies in bone metastatic diseases. *Curr Cancer Drug Targets.*, 2009 Nov; 9:834-42.
137. Civitelli R, Armamento-Villareal R, **Napoli N**. Bone turnover markers: understanding their value in clinical trials and clinical practice. *Osteoporos Int.*, 2009 Jun; 20:843-51.
138. **Napoli N**, Armamento-Villareal R. Estrogen hydroxylation in osteoporosis. *Adv Clin Chem.*, 2007; 43:211-27.
139. Civitelli, R., **Napoli N.**, Armamento-Villareal, R., Use of intravenous bisphosphonates in osteoporosis. *Curr Osteoporos Rep.*, 2007 Mar; 5:8-13.
140. **Napoli N**, Carmina, E., Role of hypogonadism in development of bone alterations in thalassemic patients. *Clin Cases Miner Bone Metab*, 2005, 2: 21-24.

## Case Reports

141. Palermo A, Strollo R, Papalia R, D'Onofrio L, Maddaloni E, Briganti SI, **Napoli N**, Vespasiani U, Costantino S, Pozzilli P, Denaro V, Manfrini S. Severe Hypophosphatemic Osteomalacia Secondary to Fanconi Syndrome Due to Adefovir: A Case Report. *Endocr Pract.*, 2014 Dec; 20:e246-9.
142. Gomberg SJ, Wustrack RL, **Napoli N**, Arnaud CD, Black DM. Teriparatide, vitamin d, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. *J Clin Endocrinol Metab.*, 2011 Jun; 96:1627-32.
143. **Napoli N**, Novack D, Armamento-Villareal R. Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. *Osteoporos Int.*, 2010 Apr; 21:705-8.
144. Armamento-Villareal R, **Napoli N**, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. *N Engl J Med.*, 2006 Nov; 355:2048-50.

## Letters

1. Leanza G, Maddaloni E, Schwartz A, **Napoli N.** Response to: Letter to editor in response to article published by Leanza et al. Bone. 2019 Oct;127:675
2. Conte C, Secchi A., **Napoli N.**, Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes. N Engl J Med., 2018 Mar; 378:966.
3. **Napoli N.**, Schwartz, A.V., Black, D.M. Reply to: Indications of Increased Vertebral Fracture Risk in Patients With Type 2 Diabetes. J Bone Miner Res., 2018 Jan; 33:183.
4. Conte C, Cecere A, Guglielmi G, **Napoli N.** GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. J Clin Endocrinol Metab., 2015 Aug; 100:2909-17.
5. **Napoli N.**, Mumm, S., Armamento-Villareal, R., CYP1A1: Ethnic and population differences in allelic frequencies and interpretation of bone biology studies. J Bone Miner Res., 2006; 21:1960-1961.

### Book Chapters

1. Pozzilli P. et al, L'Endocrinologia del Campus Bio-Medico, Edizioni Minerva Medica.
2. Conte C, Buillon R, **Napoli N.**, "Effects of Diabetes and Insulin on Bone Physiology"; Principles of Bone Biology, 2019, edited by Bilezikian JP, Elsevier
3. **Napoli N.**, Palermo A., "Diabetes, Diabetic Medications, and Risk of Fracture"; Osteoporosis, Fifth Edition, 2019, edited by Dempster D., Cauley J., Bouxsein M., Cosman F., Elsevier
4. Pozzilli P, Strollo R, **Napoli N.** Iatrogenic immunoendocrinopathy, in Immunoendocrinology: Scientific and Clinical Aspects (1st Edition). Editor, Professor Eisenbarth G. Humana Press, 2010
5. Antonelli Incalzi et al, Manuale di Geriatria; Edizioni Edra

***"Autorizzo il trattamento dei dati personali ai sensi del Regolamento UE 679/2016"***

Roma 20/12/2020

Nicola Napoli, MD PhD



